Cargando…

Population pharmacokinetic modeling of benznidazole in Brazilian patients with chronic Chagas disease

The present study aimed to establish a population pharmacokinetic (PopPK) modeling of benznidazole (BZD) in Brazilian patients with chronic Chagas disease. This was part of a Brazilian prospective cohort study with eight patients diagnosed with Chagas disease during the beginning of BZD treatment up...

Descripción completa

Detalles Bibliográficos
Autores principales:	Frade, Virgínia Paula, Moreira, Carlos Henrique Valente, Sabino, Ester Cerdeira, Bedor, Danilo César Galindo, Ghilard, Fábio de Rose, Oliveira, Cláudia Di Lorenzo, Sanches, Cristina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Instituto de Medicina Tropical de São Paulo 2022
Materias:	Brief Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8815855/ https://www.ncbi.nlm.nih.gov/pubmed/35137898 http://dx.doi.org/10.1590/S1678-9946202264004

Ejemplares similares

Benznidazole Use among Patients with Chronic Chagas' Cardiomyopathy in an Endemic Region of Brazil
por: Ferreira, Ariela Mota, et al.
Publicado: (2016)

Beneficial effects of benznidazole in Chagas disease: NIH SaMi-Trop cohort study
por: Cardoso, Clareci Silva, et al.
Publicado: (2018)

Dried Blood Spot Technique-Based Liquid Chromatography-Tandem Mass Spectrometry Method as a Simple Alternative for Benznidazole Pharmacokinetic Assessment
por: Galindo Bedor, Danilo César, et al.
Publicado: (2018)

Anti-Trypanosoma cruzi antibody profiling in patients with Chagas disease treated with benznidazole assessed by genome phage display
por: Rodriguez Carnero, Luis Antonio, et al.
Publicado: (2023)

Ideal benznidazole dose regimen in chronic chagasic patients: a systematic review
por: Frade, Virgínia Paula, et al.
Publicado: (2020)

Preclinical pharmacokinetics of benznidazole.
por: Workman, P., et al.
Publicado: (1984)

Pharmacokinetic and pharmacodynamic responses in adult patients with Chagas disease treated with a new formulation of benznidazole
por: Fernández, Marisa Liliana, et al.
Publicado: (2016)

Pharmacogenomic Profile and Adverse Drug Reactions in a Prospective Therapeutic Cohort of Chagas Disease Patients Treated with Benznidazole
por: Franco, Lucas A. M., et al.
Publicado: (2021)

Hepatic changes by benznidazole in a specific treatment for Chagas disease
por: Pavan, Tycha Bianca Sabaini, et al.
Publicado: (2018)

Access to benznidazole for Chagas disease in the United States—Cautious optimism?
por: Alpern, Jonathan D., et al.
Publicado: (2017)

Tolerance to nifurtimox and benznidazole in adult patients with chronic Chagas’ disease
por: Jackson, Yves, et al.
Publicado: (2020)

Solid Nanomedicines of Nifurtimox and Benznidazole for the Oral Treatment of Chagas Disease
por: Rolon, Miriam, et al.
Publicado: (2022)

From Benznidazole to New Drugs: Nanotechnology Contribution in Chagas Disease
por: Gomes, Daniele Cavalcante, et al.
Publicado: (2023)

Tolerance and Adherence of Patients with Chronic Chagas Disease Treated with Benznidazole
por: Vázquez, Cristina, et al.
Publicado: (2023)

The fecal, oral, and skin microbiota of children with Chagas disease treated with benznidazole
por: Robello, Carlos, et al.
Publicado: (2019)

Benznidazole, itraconazole and their combination in the treatment of acute experimental Chagas disease in dogs
por: Cunha, Eleonora Lima Alves, et al.
Publicado: (2019)

Population Pharmacokinetic Study of Benznidazole in Pediatric Chagas Disease Suggests Efficacy despite Lower Plasma Concentrations than in Adults
por: Altcheh, Jaime, et al.
Publicado: (2014)

Clinical Follow-Up of Responses to Treatment with Benznidazol in Amazon: A Cohort Study of Acute Chagas Disease
por: Pinto, Ana Yecê das Neves, et al.
Publicado: (2013)

Benznidazole and Posaconazole in Experimental Chagas Disease: Positive Interaction in Concomitant and Sequential Treatments
por: Diniz, Lívia de Figueiredo, et al.
Publicado: (2013)

Evaluation of Parasiticide Treatment with Benznidazol in the Electrocardiographic, Clinical, and Serological Evolution of Chagas Disease
por: Fragata-Filho, Abilio Augusto, et al.
Publicado: (2016)

Correction: The fecal, oral, and skin microbiota of children with Chagas disease treated with benznidazole
por: Robello, Carlos, et al.
Publicado: (2019)

Access to Chagas disease treatment in the United States after the regulatory approval of benznidazole
por: Yoshioka, Kota, et al.
Publicado: (2020)

Characterization of adverse reactions to benznidazole in patients with Chagas disease in the Federal District, Brazil
por: Gontijo, Maria Katarine Costa Lucas, et al.
Publicado: (2020)

Gut Dysbiosis in Chagas Disease. A Possible Link to the Pathogenesis
por: de Souza-Basqueira, Marcela, et al.
Publicado: (2020)

Efficacy of the Benznidazole+Posaconazole combination therapy in parasitemia reduction: An experimental murine model of acute Chagas
por: Echeverría, Luis Eduardo, et al.
Publicado: (2020)

Impact of the social context on the prognosis of Chagas disease patients: Multilevel analysis of a Brazilian cohort
por: Ferreira, Ariela Mota, et al.
Publicado: (2020)

Combination Chemotherapy with Suboptimal Doses of Benznidazole and Pentoxifylline Sustains Partial Reversion of Experimental Chagas' Heart Disease
por: Vilar-Pereira, Glaucia, et al.
Publicado: (2016)

Treatment With Suboptimal Dose of Benznidazole Mitigates Immune Response Molecular Pathways in Mice With Chronic Chagas Cardiomyopathy
por: Farani, Priscila Silva Grijó, et al.
Publicado: (2021)

Challenges in the care of patients with Chagas disease in the Brazilian public health system: A qualitative study with primary health care doctors
por: Damasceno, Renata Fiúza, et al.
Publicado: (2020)

Lack of evidence of seronegative infection in an endemic area of Chagas disease
por: de Oliveira, Léa Campos, et al.
Publicado: (2019)

Ruthenium Complex with Benznidazole and Nitric Oxide as a New Candidate for the Treatment of Chagas Disease
por: Sesti-Costa, Renata, et al.
Publicado: (2014)

Elucidating the impact of low doses of nano-formulated benznidazole in acute experimental Chagas disease
por: Rial, Marcela S., et al.
Publicado: (2017)

Looking for combination of benznidazole and Trypanosoma cruzi-triosephosphate isomerase inhibitors for Chagas disease treatment
por: Aguilera, Elena, et al.
Publicado: (2018)

Benznidazole
por: Soares-Sobrinho, José Lamartine, et al.
Publicado: (2008)

Treatment with benznidazole and pentoxifylline regulates microRNA transcriptomic profile in a murine model of Chagas chronic cardiomyopathy
por: Silva Grijó Farani, Priscila, et al.
Publicado: (2023)

Hospitalizations due to gastrointestinal Chagas disease: National registry
por: Bierrenbach, Ana Luiza, et al.
Publicado: (2022)

Benznidazole/Itraconazole Combination Treatment Enhances Anti-Trypanosoma cruzi Activity in Experimental Chagas Disease
por: Assíria Fontes Martins, Tassiane, et al.
Publicado: (2015)

Risk factors for treatment interruption and severe adverse effects to benznidazole in adult patients with Chagas disease
por: Olivera, Mario J., et al.
Publicado: (2017)

Use of benznidazole to treat chronic Chagas disease: An updated systematic review with a meta-analysis
por: Crespillo-Andújar, Clara, et al.
Publicado: (2022)

Poly-ε-Caprolactone Implants for Benznidazole Prolonged Release: An Alternative to Chagas Disease Oral Treatment
por: Mazzeti, Ana Lia, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_85bibd7dm8bj6dc9l23g1j7t5r